Effective 1 de julio de 2022, the Laboratory Tests Post Transplant and for Heart Failure policy will be updated to include the following tests: HeartCare, Prospera, and Viracor TRAC dd-cfDNA, which will require authorization for Medicare Advantage plans and will be not medically necessary for commercial products, as well as AlloSure Lung which will be not covered for Medicare Advantage plans and not medically necessary for commercial products. Additional information pertaining to the medical policy can be found here.